⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11095306 | 0.82 | — | — | |
| SCHEMBL4117138 | 0.72 | — | — | |
| SCHEMBL28066090 | 0.72 | PTGS1 (0.41) | — | |
| SCHEMBL773672 | 0.71 | TSHR (0.45) | — | |
| SCHEMBL430310 | 0.69 | — | — | |
| Alcohol SCHEMBL28212229 | 0.69 | PTGS1 (0.47) | — | |
| SCHEMBL35748 | 0.68 | — | — | |
| SCHEMBL28557026 | 0.68 | — | — | |
| SCHEMBL9193625 | 0.68 | — | — | |
| Ether SCHEMBL6677850 | 0.67 | PTGS1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | claimed |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | claimed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | claimed |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | claimed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | claimed |
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | claimed |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| US-9233978-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-01-12 | — | — | US | claimed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | claimed |
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| EP-1347780-B1 | COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES | PLIVA PHARM & CHEM WORKS (HR) | 2007-01-03 | — | — | EP | claimed |
| US-7037928-B2 | Compositions of N-(methylethylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides | PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO (HR) | 2006-05-02 | — | — | US | claimed |
| JP-2004513155-A | — | — | 2004-04-30 | — | — | JP | claimed |
| US-20040039204-A1 | Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides | PLIVA FARMACEUTSKA INDUSTRIJ, DIONICKO DRUSTVO (HR) | 2004-02-26 | — | — | US | claimed |
| EP-1347780-A1 | COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES | Pliva, Farmaceutska, Industrija, Dionicko Drustvo (HR) | 2003-10-01 | — | — | EP | claimed |
| WO-2002038186-A1 | COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES | PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO (HR) | 2002-05-16 | — | — | WO | claimed |
| WO-1998035677-A1 | NON-SEDATING HISTAMINE ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BRIDGE PHARMA, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-5561228-A | IMMUNOSUPPRESSNATS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | claimed |
| EP-4387629-A1 | 6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-0501552-A1 | 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-02 | — | — | EP | disclosed |